Utidelone and Anlotinib in Advanced Recurrent Metastatic Esophageal Cancer - Trial NCT05866510
Access comprehensive clinical trial information for NCT05866510 through Pure Global AI's free database. This Phase 2 trial is sponsored by Peking University and is currently Recruiting. The study focuses on Esophageal Cancer. Target enrollment is 47 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Peking University
Timeline & Enrollment
Phase 2
May 15, 2023
Apr 30, 2024
Primary Outcome
Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 in all participants
Summary
The goal of this clinical trial is to evaluate the safety, tolerance and efficacy of
 Utidelone combined with Anlotinib in patients with Advanced or Recurrent Esophageal Carcinoma
 who failed Standard first line therapy.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05866510
Non-Device Trial